The volume and diversity of real-world data have been growing exponentially as technology and integrated electronic medical records, and patient and physician surveys, have made this information...

The World Federation of Hemophilia (WFH) 2018 World Congress: Bayer Satellite Symposium   The XXXIII WFH World Congress took place in Glasgow, UK, on 20–24 May 2018.1  Founded by the World...

Multiple myeloma (MM) is an incurable haematological malignancy characterised by aberrant clonal proliferation of plasma cells. Multiple mutations concurrently deregulate the biological functioning...

Intravenous immunoglobulin (IVIG) can influence the immune system via multiple mechanisms including neutralisation of pathogens and anti-inflammatory effects. Its therapeutic role has expanded...

During the 2017 12th Annual Fungal Update, held in the Great Hall at St Bartholomew’s Hospital, London, on February 4th, experts reviewed new evidence on the growing threat of antifungal resistance...

3rd & 4th February 2017, St Bartholomew’s Hospital, London Dr Samir Agrawal, Chair of the Organising Committee, welcomed participants to the 12th Annual Fungal Update in the Great Hall at St...

Isavuconazole (Cresemba®), a triazole antifungal, authorised in the EU since October 2015, demonstrated clinical effectiveness in pivotal trials of invasive aspergillosis and mucormycosis, and a...

Multiple myeloma (MM) is a heterogeneous disease for which, despite the continuing advances in existing therapies such as the immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), there is...

The 2nd Spring Forum Haemophilia 2015 – ‘New Avenues in Human rFVIII Replacement: Perspectives and Challenges for the Years Ahead’– was held in Berlin, Germany, on 17 and 18 April 2015. The...

In patients with severe haemophilia it is known that the incidence of inhibitor is around 30%, the potential impact of the type of factor VIII (FVIII) product administered still being disputed.1...